Studying LAT010 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called LAT010 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have an advanced solid tumor that is growing despite standard treatments.
- You have at least one tumor that can be measured on a scan.
- You are generally able to care for yourself (ECOG score 0 or 1 for Phase 1, or 0 to 2 for Phase 2).
- Your major organs (heart, lungs, blood, liver, kidneys) are working well enough.
- You have not had IL-2 therapy in the last 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral tablet (LIT-00814) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and to find the best dose.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This trial tests a new drug called LM-24C5 for people with advanced solid tumors that have stopped responding to standard treatments or who can't tolerate them. It aims to see if the drug is safe and effective.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.